Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Ceftiofur Hydrochloride

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete Livestock/food-animal use Rx required Liquid (Suspension) Multiple FDA sponsors Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Illustration placeholder
Ceftiofur Hydrochloride

Ceftiofur Hydrochloride

Drug type: Food-animal record • Generic profile • Livestock/food-animal use

Both Liquid (Suspension) Rx required 100% reference complete

Species: Both

Approval status: Food-animal or livestock record. This source record is for livestock or food-animal use, not a dog/cat medication profile. Food-animal rules, withdrawal intervals, and residue restrictions may apply.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Ceftiofur Hydrochloride

For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis . For treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, P. multocida, and Histophilus somni ; acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus ; and acute metritis (0 to 14 days post-partum) associated with bacteria susceptible to ceftiofur. For use in lactating dairy cattle for (1) the treatment of clinical mastitis associated with coagulase-negative staphylococci, Streptococcus dysgalactiae, and Escherichia coli and (2) the treatment of diagnosed subclinical mastitis associated with coagulase-negative staphylococci and Streptococcus dysgalactiae . Species commonly shown: Both, Cattle, Excluding Veal Calves.

Generic name
Ceftiofur Hydrochloride
Brand names
Excenel® Sterile Powder Excenel® RTU Excenel Sterile Suspension, Spectramast® LC Sterile Suspension, Spectramast™ DC Sterile Suspension, EXCENEL® RTU EZ
Manufacturer
Multiple FDA sponsors
Species
Both, Cattle, Dairy, Beef And Non-Lactating Dairy
Dosage forms
Liquid (Suspension), Sterile suspension
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Excenel® Sterile Powder Excenel® RTU Excenel Sterile Suspension Spectramast® LC Sterile Suspension Spectramast™ DC Sterile Suspension EXCENEL® RTU EZ Cefenil® RTU
Dosage forms
Liquid (Suspension) Sterile suspension

Indications / Uses

For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis , and Streptococcus suis . For treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, P. multocida, and Histophilus somni ; acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus ; and acute metritis (0 to 14 days post-partum) associated with bacteria susceptible to ceftiofur. For use in lactating dairy cattle for (1) the treatment of clinical mastitis associated with coagulase-negative staphylococci, Streptococcus dysgalactiae , and Escherichia coli and (2) the treatment of diagnosed subclinical mastitis associated with coagulase-negative staphylococci and Streptococcus dysgalactiae .

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated cattle must not be slaughtered for 3 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption. Following label use for up to eight consecutive days, a 2-day pre-slaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal Law prohibits extra-label use of this drug in lactating dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes.

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated cattle must not be slaughtered for 3 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption. Following label use for up to eight consecutive days, a 2-day pre-slaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal Law prohibits extra-label use of this drug in lactating dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes.

Side Effects

Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia.

FAQ

Both, Cattle, Excluding Veal Calves, Dairy, lactating, Dairy, dry cows, Beef And Non-Lactating Dairy

Yes. Roxee shows this as prescription-only.

Liquid (Suspension), Sterile suspension

Related Conditions

Mastitis Metritis Pneumonia (aspiration, bacterial, viral) Pododermatitis

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For treatment of Acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus .

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Treated swine must not be slaughtered for 4 days following the last treatment
  • Treated cattle must not be slaughtered for 3 days following the last treatment
  • A withdrawal period has not been established in preruminating calves
  • Do not use in calves to be processed for veal
  • Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption
  • Following label use for up to eight consecutive days, a 2-day pre-slaughter withdrawal period is required
  • Federal Law prohibits extra-label use of this drug in lactating dairy cattle for disease prevention purposes
  • at unapproved doses
  • frequencies, durations, or routes of administration
  • and in unapproved major food producing species/production classes
  • Vomiting (1 reports)
  • very low energy (1 reports)
  • Shaking (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Ceftiofur Hydrochloride; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2026-US-008467
Safety signal coverage Reported signals

18 tracked reaction signals; 15 reported cases; 12 serious reports; 1 species group. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2026-US-008467
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2026-US-008467
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Vomiting (1 reports), Tiredness (lethargy) (1 reports), Shaking (1 reports), Proprioception deficit (1 reports), Polydipsia (1 reports)

Body systems represented Signal grouping

Digestive (2), Skin & allergy (2), Neurologic (2), Other (12)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (18 reports)

Breed metadata in reports Metadata only

Dachshund (unspecified) (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Ceftiofur Hydrochloride fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Treated swine must not be slaughtered for 4 days following the last treatment, Treated cattle must not be slaughtered for 3 days following the last treatment, A withdrawal period has not been established in preruminating calves, Do not use in calves to be processed for veal, Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after th

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Ceftiofur Hydrochloride brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2026-US-008467 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. FOI · document · documents
  8. FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: April 22, 2026, 10:07 AM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Treated swine must not be slaughtered for 4 days following the last treatment
  • Treated cattle must not be slaughtered for 3 days following the last treatment
  • A withdrawal period has not been established in preruminating calves
  • Do not use in calves to be processed for veal
  • Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption

Most reported reactions:

  • Vomiting (1 reports)
  • Tiredness (lethargy) (1 reports)
  • Shaking (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Beef And Non-Lactating Dairy, Cattle, Dairy
Indication / use
For treatment of Acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus .
Form / route / dose
Form: Liquid (Suspension), Sterile suspension
Route: Injection, Intramammary, Intramuscular, Subcutaneous
Confirm product label and patient-specific plan.
Warnings
  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaught…
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA sponsors
Form: Liquid (Suspension), Sterile suspension
Identifiers:
ANADA: 200616 NADA: 140890 NADA: 141238 NADA: 141239 NADA: 141288 NDC Package: 54771-5278-1 NDC Package: 54771-5278-2 NDC Package: 54771-5279-1 NDC Package: 54771-5279-2 NDC Package: 54771-5402-1 NDC Package: 54771-5402-2 NDC Package: 55529-163-02 NDC Package: 55529-163-04 NDC Product: 54771 NDC Product: 55529
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated cattle must not be slaughtered for 3 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption. Following label use for up to eight consecutive days, a 2-day pre-slaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal Law prohibits extra-label use of this drug in lactating dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated cattle must not be slaughtered for 3 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption. Following label use for up to eight consecutive days, a 2-day pre-slaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal Law prohibits extra-label use of this drug in lactating dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
1
Matching reports
1
Active filters
0
Reset
Drill into common report signals
Blindness (1) Other (1)
Showing up to 50 matching reports.

USA-USFDACVM-2026-US-008467

Received 2026-02-26 · MSK · MSK

Serious
Species
Dog
Breed
Dachshund (unspecified)
Size / weight
10-24 lb (6.8 Kilogram)
Age
4-7 years (6 Year)
Sex
Female Neutered
Region
USA
Reactions
Blindness
Body systems
Other
Outcomes
Ongoing

Tap or hover a reaction to see what it means in plain language.

Tracked signals
18
Reported cases
15
Serious reports
12
Species represented
1
Grouped by Body System
Digestive (2) · Vomiting, Bloody diarrhoea Skin & allergy (2) · Hives, Hives (see also 'Skin') Neurologic (2) · Tiredness (lethargy), Lethargy (see also Central nervous system depression in 'Neurological') Other (12) · Swollen eye, Shaking, Rubbing
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Dog 1
Neurologic 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (18)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Serious - 1
Neurologic Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Skin & allergy Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Neurologic Dog Unknown - -
Skin & allergy Dog Unknown - -
Other Dog Unknown - -
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

140-890 Official label / PI · EA 140-890 Official label / PI · FONSI 140-890 Official label / PI · EA

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

4

SPL

7

FOI

15

140-890

Official label / PI · EA

Open original

140-890

Official label / PI · FONSI

Open original

140-890

Official label / PI · EA

Open original

140-890

Official label / PI · FONSI

Open original

EXCENEL® RTU EZ

SPL · SPL

Open original
FDA Structured Product Label

EXCENEL® RTU EZ

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
141-288
Status
RX
Form
Liquid (Suspension)
Route
Intramuscular, Subcutaneous
Species
Beef And Non-Lactating Dairy • Dairy
Composition / specifications
Each mL contains 50 mg of ceftiofur equivalents (CE).

Cattle (Beef, Non-Lactating Dairy, Lactating Dairy)

Indication
For treatment of Acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.
Dosage
Administer by intramuscular or subcutaneous administration 0.5 to 1 mg CE/lb (1.1 to 2.2 mg CE/kg) BW (1 to 2 mL sterile suspension per 100 lb BW). Administer daily at 24-hour intervals for a total of three consecutive days. Additional treatments may be administered on Days 4 and 5 for animals which do not show a satisfactory response (not recovered) after the initial three treatments.
Indication
For treatment of Acute metritis (0 to 14 days post-partum) associated with bacterial organisms susceptible to ceftiofur.
Dosage

Administer by intramuscular or subcutaneous administration at the dosage of 1 mg CE/lb (2.2 mg CE/kg) BW (2 mL sterile suspension per 100 lb BW). Administer at 24 hour intervals for five consecutive days. Do not inject more than 15 mL per injection site.

Indication
For treatment of Bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
Dosage

Administer by intramuscular or subcutaneous administration at the dosage of 0.5 to 1 mg CE/lb (1.1 to 2.2 mg CE/kg) BW (1 to 2 mL sterile suspension per 100 lb BW). Administer daily at 24 hour intervals for a total of three consecutive days. Additional treatments may be administered on Days 4 and 5 for animals which do not show a satisfactory response (not recovered) after the initial three treatments. Alternatively, for BRD only, administer intramuscularly or subcutaneously 1 mg CE/ lb (2.2 mg CE/kg) BW every other day on Days 1 and 3 (48 hour interval). Selection of dosage level (0.5 to 1 mg CE/lb) and regimen/duration (daily or every other day for BRD only) should be based on an assessment of the severity of disease, pathogen susceptibility and clinical response. Do not inject more than 15 mL per injection site.

Swine

Indication
For treatment/control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella Choleraesuis and Streptococcus suis.
Dosage

Administer intramuscularly at a dosage of 1.36 to 2.27 mg ceftiofur equivalents (CE)/lb (3 to 5 mg CE/kg) body weight (BW) (1 mL of sterile suspension per 22 to 37 lb BW). Treatment should be repeated at 24 hour intervals for a total of three consecutive days. Do not inject more than 15 mL per injection site.

Cefenil® RTU

SPL · SPL

Open original
FDA Structured Product Label

Cefenil® RTU

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Norbrook Laboratories, Ltd.
ANADA
200-616
Status
RX
Form
Sterile suspension
Route
Injection
Composition / specifications
50 mg/mL

Swine

Indication

For treatment/control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus (Haemophilus) pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis and Streptococcus suis.

Dosage

Administer intramuscularly at a dosage of 1.36 to 2.27 mg ceftiofur equivalents/lb (3.0 to 5.0 mg/kg) BW (1 mL of sterile suspension per 22 to 37 lb BW). Treatment should be repeated at 24 h intervals for a total of three consecutive days.

Cattle

Indication

For treatment of the following bacterial diseases:

  • Bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
  • Acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.
  • Acute metritis (0 to 14 days post-partum) associated with bacterial organisms susceptible to ceftiofur.
Dosage

For bovine respiratory disease and acute bovine interdigital necrobacillosis: administer by intramuscular or subcutaneous administration at the dosage of 0.5 to 1.0 mg ceftiofur equivalents/lb (1.1 to 2.2 mg/kg) BW (1 to 2 mL sterile suspension per 100 lb BW). Administer daily at 24 h intervals for a total of three consecutive days. Additional treatments may be administered on Days 4 and 5 for animals which do not show a satisfactory response (not recovered) after the initial three treatments. In addition, for BRD only, administer intramuscularly or subcutaneously 1.0 mg ceftiofur equivalents/lb (2.2 mg/kg) BW every other day on Days 1 and 3 (48 h interval). Do not inject more than 15 mL per injection site. Selection of dosage level (0.5 to 1.0 mg/lb) and regimen/duration (daily or every other day for BRD only) should be based on an assessment of the severity of disease, pathogen susceptibility and clinical response. For acute post-partum metritis: administer by intramuscular or subcutaneous administration at the dosage of 1.0 mg ceftiofur equivalents/lb (2.2 mg/kg) BW (2 mL sterile suspension per 100 lb BW). Administer at 24 h intervals for five consecutive days. Do not inject more than 15 mL per injection site.

Excenel® Sterile Powder

SPL · SPL

Open original
FDA Structured Product Label

Excenel® Sterile Powder Excenel® RTU Excenel Sterile Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
140-890
Status
RX
Form
Liquid (Suspension)
Route
Subcutaneous, Intramuscular
Species
Cattle
Composition / specifications
Each milliliter of ceftiofur hydrochloride suspension contains 50 milligrams (mg) of ceftiofur equivalents.

Swine

Indication
For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis.
Dosage
3 to 5 milligrams per kilogram of body weight by intramuscular injection. Treatment should be repeated at 24-hour intervals for a total of 3 consecutive days.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treatment.

Cattle (excluding veal calves)

Indication
For treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, P. multocida, and Histophilus somni; acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus; and acute metritis (0 to 14 days post-partum) associated with bacteria susceptible to ceftiofur.
Dosage
1.1 to 2.2 mg/kg of body weight by intramuscular or subcutaneous injection, at 24-hour intervals for 3 to 5 consecutive days. For bovine respiratory disease, 2.2 mg/kg of body weight may be administered twice at a 48-hour interval. For acute metritis, administer 2.2 mg/kg of body weight daily for 5 consecutive days.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated cattle must not be slaughtered for 3 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Excenel® RTU

SPL · SPL

Open original
FDA Structured Product Label

Excenel® Sterile Powder Excenel® RTU Excenel Sterile Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
140-890
Status
RX
Form
Liquid (Suspension)
Route
Subcutaneous, Intramuscular
Species
Cattle
Composition / specifications
Each milliliter of ceftiofur hydrochloride suspension contains 50 milligrams (mg) of ceftiofur equivalents.

Swine

Indication
For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis.
Dosage
3 to 5 milligrams per kilogram of body weight by intramuscular injection. Treatment should be repeated at 24-hour intervals for a total of 3 consecutive days.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treatment.

Cattle (excluding veal calves)

Indication
For treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, P. multocida, and Histophilus somni; acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus; and acute metritis (0 to 14 days post-partum) associated with bacteria susceptible to ceftiofur.
Dosage
1.1 to 2.2 mg/kg of body weight by intramuscular or subcutaneous injection, at 24-hour intervals for 3 to 5 consecutive days. For bovine respiratory disease, 2.2 mg/kg of body weight may be administered twice at a 48-hour interval. For acute metritis, administer 2.2 mg/kg of body weight daily for 5 consecutive days.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated cattle must not be slaughtered for 3 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Excenel Sterile Suspension

SPL · SPL

Open original
FDA Structured Product Label

Excenel® Sterile Powder Excenel® RTU Excenel Sterile Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
140-890
Status
RX
Form
Liquid (Suspension)
Route
Subcutaneous, Intramuscular
Species
Cattle
Composition / specifications
Each milliliter of ceftiofur hydrochloride suspension contains 50 milligrams (mg) of ceftiofur equivalents.

Swine

Indication
For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis.
Dosage
3 to 5 milligrams per kilogram of body weight by intramuscular injection. Treatment should be repeated at 24-hour intervals for a total of 3 consecutive days.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treatment.

Cattle (excluding veal calves)

Indication
For treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, P. multocida, and Histophilus somni; acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus; and acute metritis (0 to 14 days post-partum) associated with bacteria susceptible to ceftiofur.
Dosage
1.1 to 2.2 mg/kg of body weight by intramuscular or subcutaneous injection, at 24-hour intervals for 3 to 5 consecutive days. For bovine respiratory disease, 2.2 mg/kg of body weight may be administered twice at a 48-hour interval. For acute metritis, administer 2.2 mg/kg of body weight daily for 5 consecutive days.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated cattle must not be slaughtered for 3 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Spectramast™ DC Sterile Suspension

SPL · SPL

Open original
FDA Structured Product Label

Spectramast™ DC Sterile Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
141-239
Status
RX
Form
Liquid (Suspension)
Route
Intramammary
Species
Dairy
Composition / specifications
Each single-use, 10-milliliter syringe of ceftiofur hydrochloride suspension contains or 500 milligrams (mg)ceftiofur equivalents.

Dairy cattle (At Dry Off)

Indication
For the treatment of subclinical mastitis in dairy cattle at the time of dry off associated with Staphylococcus aureus, Streptococcus dysgalactiae, and Streptococcus uberis.
Dosage
Infuse 500 mg per affected quarter at the time of dry off.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Spectramast® LC Sterile Suspension

SPL · SPL

Open original
FDA Structured Product Label

Spectramast® LC Sterile Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
141-238
Status
RX
Form
Liquid (Suspension)
Route
Intramammary
Species
Dairy
Composition / specifications
Each single-use, 10-milliliter syringe of ceftiofur hydrochloride suspension contains 125 milligrams (mg) ceftiofur equivalents.

Lactating Dairy Cattle

Indication
For use in lactating dairy cattle for (1) the treatment of clinical mastitis associated with coagulase-negative staphylococci, Streptococcus dysgalactiae, and Escherichia coli and (2) the treatment of diagnosed subclinical mastitis associated with coagulase-negative staphylococci and Streptococcus dysgalactiae.
Dosage
Infuse 125 mg per affected quarter. Repeat treatment in 24 hours. Once daily treatment may be repeated for up to 8 consecutive days.
Limitations
Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption. Following label use for up to eight consecutive days, a 2-day pre-slaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal Law prohibits extra-label use of this drug in lactating dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes.

FOI Summary sN 141-288 Approved May 6, 2019.pdf

FOI · FOI

Open original

UCM377873.pdf

FOI · FOI

Open original

UCM208544.pdf

FOI · FOI

Open original

FOI Summary oA 200-616 Approved January 28, 2019.pdf

FOI · FOI

Open original

ucm059129.pdf

FOI · FOI

Open original

ucm059128.pdf

FOI · FOI

Open original

ucm059127.pdf

FOI · FOI

Open original

ucm059124.pdf

FOI · FOI

Open original

ucm059122.pdf

FOI · FOI

Open original

ucm059120.pdf

FOI · FOI

Open original

ucm118055.pdf

FOI · FOI

Open original

ucm118053.pdf

FOI · FOI

Open original

UCM446090.pdf

FOI · FOI

Open original

ucm118052.pdf

FOI · FOI

Open original

ucm118051.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Beef And Non-Lactating Dairy, Cattle, Dairy
Rx/OTC: RX
Form/route: Liquid (Suspension), Sterile suspension • Injection, Intramammary, Intramuscular, Subcutaneous
Applications: NADA 141-288 • ANADA 200-616 • NADA 140-890 • NADA 141-239 • NADA 141-238
Documents: 19 (FOI: 15) • SPL: 7 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 1 • Cat 0 • View
Case summaries: 1 (showing 1) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated cattle must not be slaughtered for 3 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption. Following label use for up to eight consecutive days, a 2-day pre-slaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal Law prohibits extra-label use of this drug in lactating dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes. (Contraindication, High)
Top reaction signals
Vomiting (1) Tiredness (lethargy) (1) Shaking (1) Proprioception deficit (1) Polydipsia (1) Panting (1) Hypothermia (1) Elevated alanine aminotransferase (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200616 NADA: 140890 NADA: 141238 NADA: 141239 NADA: 141288 NDC Package: 54771-5278-1 NDC Package: 54771-5278-2 NDC Package: 54771-5279-1 NDC Package: 54771-5279-2 NDC Package: 54771-5402-1 NDC Package: 54771-5402-2 NDC Package: 55529-163-02 NDC Package: 55529-163-04 NDC Product: 54771 NDC Product: 55529
Package NDC Product NDC Form / Route Status
54771-5278-1 54771 -
54771-5278-2 54771 -
54771-5279-1 54771 -
54771-5279-2 54771 -
54771-5402-1 54771 -
54771-5402-2 54771 -
55529-163-02 55529 -
55529-163-04 55529 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • UCM208544.pdf • FOI summary • Official • June 3, 2019
    FDA FOI summary for application 141288
  • UCM377873.pdf • FOI summary • Official • June 3, 2019
    FDA FOI summary for application 141288
  • FOI Summary sN 141-288 Approved May 6, 2019.pdf • FOI summary • Official • June 3, 2019
    FDA FOI summary for application 141288
  • FOI Summary oA 200-616 Approved January 28, 2019.pdf • FOI summary • Official • Jan. 31, 2019
    FDA FOI summary for application 200616
  • ucm059120.pdf • FOI summary • Official • Dec. 18, 2017
    FDA FOI summary for application 140890
  • ucm059122.pdf • FOI summary • Official • Dec. 18, 2017
    FDA FOI summary for application 140890
  • ucm059124.pdf • FOI summary • Official • Dec. 18, 2017
    FDA FOI summary for application 140890
  • ucm059127.pdf • FOI summary • Official • Dec. 18, 2017
    FDA FOI summary for application 140890
  • ucm059128.pdf • FOI summary • Official • Dec. 18, 2017
    FDA FOI summary for application 140890
  • ucm059129.pdf • FOI summary • Official • Dec. 18, 2017
    FDA FOI summary for application 140890
  • ucm118053.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 141239
  • ucm118055.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 141239
  • ucm118051.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 141238
  • ucm118052.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 141238
  • UCM446090.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 141238

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 60 Clinical 75 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treat… (Clinical, 2026-04-15)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treat… (Clinical, 2026-04-11)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-07-02)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-07-01)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-07-01)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-07-01)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-30)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-25)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-24)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-24)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-23)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-22)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-22)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-21)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-20)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-13)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-12)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-12)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-11)
  • side_effects: Top reported reactions (openFDA): Bloody diarrhoea, Death, Dehydration, Elevated alanine aminotransferase (ALT), Hives (see also 'Skin'), Hypothermia. (Clinical, 2026-06-11)
Recent Revisions
  • side_effects updated 2026-07-22 19:08 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-07-22 19:08 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-07-22 19:08 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-07-22 18:40 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-07-22 18:40 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-07-22 18:40 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-07-22 08:29 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-07-22 08:29 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-07-22 08:29 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-07-20 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-07-20 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-07-20 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-07-19 13:48 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-07-19 13:48 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-07-19 13:48 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-07-16 16:34 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-07-16 16:34 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-07-16 16:34 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-07-16 15:43 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-07-16 15:43 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
EXCENEL® RTU EZ
RX
Ceftiofur Hydrochloride
Liquid (Suspension) • Intramuscular, Subcutaneous
Label highlights
Official documents
Zoetis Inc. NADA 141-288 Approved Jun 3, 2019
Cefenil® RTU
RX
Ceftiofur Hydrochloride
Sterile suspension • Injection
Label highlights
Official documents
Norbrook Laboratories, Ltd. ANADA 200-616 Approved Jan 31, 2019
Excenel® Sterile Powder Excenel® RTU Excenel Sterile Suspension
RX
Ceftiofur Hydrochloride
Liquid (Suspension) • Subcutaneous, Intramuscular
Label highlights
Official documents
Zoetis Inc. NADA 140-890 Approved Dec 18, 2017
Spectramast™ DC Sterile Suspension
RX
Ceftiofur Hydrochloride
Liquid (Suspension) • Intramammary
Label highlights
Official documents
Zoetis Inc. NADA 141-239 Approved Jun 1, 2016
Spectramast® LC Sterile Suspension
RX
Ceftiofur Hydrochloride
Liquid (Suspension) • Intramammary
Label highlights
Official documents
Zoetis Inc. NADA 141-238 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Beef And Non-Lactating Dairy • Dairy
Composition / specifications
Each mL contains 50 mg of ceftiofur equivalents (CE).
Cattle (Beef, Non-Lactating Dairy, Lactating Dairy)
Indication
For treatment of Acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.
Dosage
Administer by intramuscular or subcutaneous administration 0.5 to 1 mg CE/lb (1.1 to 2.2 mg CE/kg) BW (1 to 2 mL sterile suspension per 100 lb BW). Administer daily at 24-hour intervals for a total of three consecutive days. Additional treatments may be administered on Days 4 and 5 for animals which do not show a satisfactory response (not recovered) after the initial three treatments.
Limitations
Indication
For treatment of Acute metritis (0 to 14 days post-partum) associated with bacterial organisms susceptible to ceftiofur.
Dosage

Administer by intramuscular or subcutaneous administration at the dosage of 1 mg CE/lb (2.2 mg CE/kg) BW (2 mL sterile suspension per 100 lb BW). Administer at 24 hour intervals for five consecutive days. Do not inject more than 15 mL per injection site.

Limitations
Indication
For treatment of Bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
Dosage

Administer by intramuscular or subcutaneous administration at the dosage of 0.5 to 1 mg CE/lb (1.1 to 2.2 mg CE/kg) BW (1 to 2 mL sterile suspension per 100 lb BW). Administer daily at 24 hour intervals for a total of three consecutive days. Additional treatments may be administered on Days 4 and 5 for animals which do not show a satisfactory response (not recovered) after the initial three treatments. Alternatively, for BRD only, administer intramuscularly or subcutaneously 1 mg CE/ lb (2.2 mg CE/kg) BW every other day on Days 1 and 3 (48 hour interval). Selection of dosage level (0.5 to 1 mg CE/lb) and regimen/duration (daily or every other day for BRD only) should be based on an assessment of the severity of disease, pathogen susceptibility and clinical response. Do not inject more than 15 mL per injection site.

Limitations
Swine
Indication
For treatment/control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella Choleraesuis and Streptococcus suis.
Dosage

Administer intramuscularly at a dosage of 1.36 to 2.27 mg ceftiofur equivalents (CE)/lb (3 to 5 mg CE/kg) body weight (BW) (1 mL of sterile suspension per 22 to 37 lb BW). Treatment should be repeated at 24 hour intervals for a total of three consecutive days. Do not inject more than 15 mL per injection site.

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications
50 mg/mL
Swine
Indication

For treatment/control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus (Haemophilus) pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis and Streptococcus suis.

Dosage

Administer intramuscularly at a dosage of 1.36 to 2.27 mg ceftiofur equivalents/lb (3.0 to 5.0 mg/kg) BW (1 mL of sterile suspension per 22 to 37 lb BW). Treatment should be repeated at 24 h intervals for a total of three consecutive days.

Limitations
Cattle
Indication

For treatment of the following bacterial diseases:

  • Bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
  • Acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.
  • Acute metritis (0 to 14 days post-partum) associated with bacterial organisms susceptible to ceftiofur.
Dosage

For bovine respiratory disease and acute bovine interdigital necrobacillosis: administer by intramuscular or subcutaneous administration at the dosage of 0.5 to 1.0 mg ceftiofur equivalents/lb (1.1 to 2.2 mg/kg) BW (1 to 2 mL sterile suspension per 100 lb BW). Administer daily at 24 h intervals for a total of three consecutive days. Additional treatments may be administered on Days 4 and 5 for animals which do not show a satisfactory response (not recovered) after the initial three treatments. In addition, for BRD only, administer intramuscularly or subcutaneously 1.0 mg ceftiofur equivalents/lb (2.2 mg/kg) BW every other day on Days 1 and 3 (48 h interval). Do not inject more than 15 mL per injection site. Selection of dosage level (0.5 to 1.0 mg/lb) and regimen/duration (daily or every other day for BRD only) should be based on an assessment of the severity of disease, pathogen susceptibility and clinical response. For acute post-partum metritis: administer by intramuscular or subcutaneous administration at the dosage of 1.0 mg ceftiofur equivalents/lb (2.2 mg/kg) BW (2 mL sterile suspension per 100 lb BW). Administer at 24 h intervals for five consecutive days. Do not inject more than 15 mL per injection site.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Cattle
Composition / specifications
Each milliliter of ceftiofur hydrochloride suspension contains 50 milligrams (mg) of ceftiofur equivalents.
Swine
Indication
For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis.
Dosage
3 to 5 milligrams per kilogram of body weight by intramuscular injection. Treatment should be repeated at 24-hour intervals for a total of 3 consecutive days.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treatment.
Cattle (excluding veal calves)
Indication
For treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, P. multocida, and Histophilus somni; acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus; and acute metritis (0 to 14 days post-partum) associated with bacteria susceptible to ceftiofur.
Dosage
1.1 to 2.2 mg/kg of body weight by intramuscular or subcutaneous injection, at 24-hour intervals for 3 to 5 consecutive days. For bovine respiratory disease, 2.2 mg/kg of body weight may be administered twice at a 48-hour interval. For acute metritis, administer 2.2 mg/kg of body weight daily for 5 consecutive days.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated cattle must not be slaughtered for 3 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dairy
Composition / specifications
Each single-use, 10-milliliter syringe of ceftiofur hydrochloride suspension contains or 500 milligrams (mg)ceftiofur equivalents.
Dairy cattle (At Dry Off)
Indication
For the treatment of subclinical mastitis in dairy cattle at the time of dry off associated with Staphylococcus aureus, Streptococcus dysgalactiae, and Streptococcus uberis.
Dosage
Infuse 500 mg per affected quarter at the time of dry off.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dairy
Composition / specifications
Each single-use, 10-milliliter syringe of ceftiofur hydrochloride suspension contains 125 milligrams (mg) ceftiofur equivalents.
Lactating Dairy Cattle
Indication
For use in lactating dairy cattle for (1) the treatment of clinical mastitis associated with coagulase-negative staphylococci, Streptococcus dysgalactiae, and Escherichia coli and (2) the treatment of diagnosed subclinical mastitis associated with coagulase-negative staphylococci and Streptococcus dysgalactiae.
Dosage
Infuse 125 mg per affected quarter. Repeat treatment in 24 hours. Once daily treatment may be repeated for up to 8 consecutive days.
Limitations
Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption. Following label use for up to eight consecutive days, a 2-day pre-slaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal Law prohibits extra-label use of this drug in lactating dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes.

FDA page: Open in Animal Drugs @ FDA

Usage

For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis , and Streptococcus suis . For treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, P. multocida, and Histophilus somni ; acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus ; and acute metritis (0 to 14 days post-partum) associated with bacteria susceptible to ceftiofur. For use in lactating dairy cattle for (1) the treatment of clinical mastitis associated with coagulase-negative staphylococci, Streptococcus dysgalactiae , and Escherichia coli and (2) the treatment of diagnosed subclinical mastitis associated with coagulase-negative staphylococci and Streptococcus dysgalactiae .

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated swine must not be slaughtered for 4 days following the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Treated cattle must not be slaughtered for 3 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption. Following label use for up to eight consecutive days, a 2-day pre-slaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal Law prohibits extra-label use of this drug in lactating dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Dog Bloody diarrhoea (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Hives (1) • Dog

Showing top 5 for Skin & allergy.

Neurologic
Tiredness (1) • Dog Tiredness (lethargy) • Dog

Showing top 5 for Neurologic.

Other
Swollen eye (1) • Dog Shaking (1) • Dog Rubbing (1) • Dog Proprioception deficit (1) • Dog Polydipsia (1) • Dog
Show more (6)
Panting (1) • Dog Hypothermia (1) • Dog Elevated alanine aminotransferase (1) • Dog Dehydration (1) • Dog Death (1) • Dog Blindness (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Dachshund (unspecified), Female, 6 year, 6.8 kilogram • Drug: MSK, Parenteral • Reactions: Blindness • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-008467
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 6.00 Year
  • Weight: 6.800 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Parenteral
Reactions Reported:
Blindness
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.